KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Average (2016 - 2025)

CRISPR Therapeutics AG's Equity Average history spans 10 years, with the latest figure at $1.9 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 0.88% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, down 0.88%, while the annual FY2025 figure was $1.9 billion, 1.02% up from the prior year.
  • Equity Average for Q4 2025 was $1.9 billion at CRISPR Therapeutics AG, up from $1.8 billion in the prior quarter.
  • Across five years, Equity Average topped out at $2.6 billion in Q3 2021 and bottomed at $1.7 billion in Q1 2021.
  • The 5-year median for Equity Average is $1.9 billion (2024), against an average of $2.0 billion.
  • The largest annual shift saw Equity Average soared 145.4% in 2021 before it fell 22.05% in 2022.
  • A 5-year view of Equity Average shows it stood at $2.5 billion in 2021, then dropped by 22.05% to $1.9 billion in 2022, then fell by 5.71% to $1.8 billion in 2023, then rose by 7.23% to $1.9 billion in 2024, then fell by 0.88% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Equity Average are $1.9 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025).